Journal article
Targeted therapy for metastatic renal cell carcinoma
Abstract
BACKGROUND: Several comparative randomised controlled trials (RCTs) have been performed including combinations of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors since the publication of a Cochrane Review on targeted therapy for metastatic renal cell carcinoma (mRCC) in 2008. This review represents an update of that original review.
OBJECTIVES: To assess the effects of targeted therapies for clear cell mRCC in patients naïve …
Authors
Hofmann F; Hwang EC; Lam TB; Bex A; Yuan Y; Marconi LS; Ljungberg B
Journal
Cochrane Database of Systematic Reviews, Vol. 2020, No. 10,
Publisher
Wiley
DOI
10.1002/14651858.cd012796.pub2
ISSN
1361-6137
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAntineoplastic Agents, ImmunologicalAxitinibBevacizumabBiasCarcinoma, Renal CellEverolimusHumansIndazolesIpilimumabKidney NeoplasmsPhenylurea CompoundsProgression-Free SurvivalProtein Kinase InhibitorsPyrimidinesQuality of LifeQuinolinesRandomized Controlled Trials as TopicReceptors, Vascular Endothelial Growth FactorSirolimusSorafenibSulfonamidesSunitinib